Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if HIV-specific canarypox vaccine and/or
interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment
is withdrawn for a certain time period.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)